Satellos Bioscience (TSX:MSCL) ROCE % : -60.07% (As of Dec. 2023)

View and export this data going back to 2021. Start your Free Trial

What is Satellos Bioscience ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Satellos Bioscience's annualized ROCE % for the quarter that ended in Dec. 2023 was -60.07%.

Satellos Bioscience ROCE % Historical Data

The historical data trend for Satellos Bioscience's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Satellos Bioscience ROCE % Chart

Satellos Bioscience Annual Data

Trend

Dec20

Dec21

Dec22

Dec23

ROCE %

-171.07

-254.94

-163.41

-71.35

Satellos Bioscience Quarterly Data
	Jun20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
ROCE %	Get a 7-Day Free Trial									-350.16	-180.57	-58.16	-28.88	-60.07

Satellos Bioscience ROCE % Calculation

Satellos Bioscience's annualized ROCE % for the fiscal year that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	-15.712	/	( ( (6.199 - 2.83)	+	(44.298 - 3.624) )	/ 2 )
	=	-15.712	/	( (3.369	+	40.674)	/ 2 )
	=	-15.712	/	22.0215
	=	-71.35 %

Satellos Bioscience's ROCE % of for the quarter that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Dec. 2023 )		(Q: Sep. 2023 )		(Q: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Dec. 2023 )		(Q: Sep. 2023 )		(Q: Dec. 2023 )
	=	-26.14	/	( ( (48.676 - 2.317)	+	(44.298 - 3.624) )	/ 2 )
	=	-26.14	/	( ( 46.359	+	40.674 )	/ 2 )
	=	-26.14	/	43.5165
	=	-60.07 %

(1) Note: The EBIT data used here is four times the quarterly (Dec. 2023) EBIT data.

Satellos Bioscience (TSX:MSCL) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Satellos Bioscience ROCE % Related Terms

Thank you for viewing the detailed overview of Satellos Bioscience's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Satellos Bioscience (TSX:MSCL) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Satellos Bioscience Inc (TSX:MSCL) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

MSCLF:USA 0IT:Germany

Address

65 Front Street East, Suite 201, Toronto, ON, CAN, M5E 1B5

Website

https://www.satellos.com

Satellos Bioscience Inc is a regenerative medicine company dedicated to developing novel therapeutics that stimulate or restore muscle regeneration in severe disorders. Its lead program is focused on developing an oral therapeutic drug for Duchenne muscular dystrophy that serves to correct this dysregulation which Satellos has identified as a root cause of the progressive nature of this disease.

Satellos Bioscience (TSX:MSCL) Headlines

No Headlines